Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Affimed N.V. (AFMD)

2.06   0.03 (1.48%) 10-01 10:43
Open: 2.03 Pre. Close: 2.03
High: 2.22 Low: 2.03
Volume: 1,043,181 Market Cap: 308(M)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.22 - 2.23 2.23 - 2.24
Low: 2 - 2.02 2.02 - 2.03
Close: 2.04 - 2.06 2.06 - 2.08

Technical analysis

as of: 2022-09-30 4:26:00 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.02     One year: 3.5
Support: Support1: 1.92    Support2: 1.6
Resistance: Resistance1: 2.59    Resistance2: 3
Pivot: 2.21
Moving Average: MA(5): 2.03     MA(20): 2.31
MA(100): 2.82     MA(250): 4.14
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 16.4     %D(3): 13.5
RSI: RSI(14): 35.4
52-week: High: 7.34  Low: 1.92
Average Vol(K): 3-Month: 989 (K)  10-Days: 1,057 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AFMD ] has closed above bottom band by 35.4%. Bollinger Bands are 34.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 27 Sep 2022
Lows Outpace Highs Tuesday; Stocks Mixed - InvestorsObserver

Wed, 21 Sep 2022
Should You Buy Affimed NV (AFMD) Stock on Wednesday? - InvestorsObserver

Tue, 20 Sep 2022
Stocks Fall Tuesday; Lows Outpace Highs Ahead of Fed Rate Decision Wednesday - InvestorsObserver

Sun, 04 Sep 2022
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022 - GlobeNewswire

Thu, 11 Aug 2022
Affimed NV (AFMD) CEO Adi Hoess on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Mon, 08 Aug 2022
Recent uptick might appease Affimed N.V. (NASDAQ:AFMD) institutional owners after losing 51% over the past year - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 149 (M)
Shares Float 124 (M)
% Held by Insiders 3.4 (%)
% Held by Institutions 68.5 (%)
Shares Short 4,050 (K)
Shares Short P.Month 4,530 (K)

Stock Financials

EPS -0.66
EPS Est Next Qtl -0.21
EPS Est This Year -0.84
EPS Est Next Year -0.8
Book Value (p.s.) 1.28
Profit Margin (%) -213.1
Operating Margin (%) -227.5
Return on Assets (ttm) -20
Return on Equity (ttm) -44.4
Qtrly Rev. Growth -24.9
Gross Profit (p.s.) 0.27
Sales Per Share 0.23
EBITDA (p.s.) -0.54
Qtrly Earnings Growth 0
Operating Cash Flow -108 (M)
Levered Free Cash Flow -67 (M)

Stock Valuations

PE Ratio -3.13
PEG Ratio 0
Price to Book value 1.59
Price to Sales 8.59
Price to Cash Flow -2.85

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.